The World Congress on Leishmaniasis which takes place every four years, is an opportunity for experts from around the world to discuss current research in the field of leishmaniasis. This year the event was held on 3-7 February, in Lucknow, India. DNDi organised two treatment related symposia: a plenary session on ‘Improved Treatments for VL – Status of Ongoing Studies, and Challenges and Opportunities Ahead’, as well as a parallel one on ‘Challenges for and Potential in the Early-Stage R&D Pipeline to Develop New Anti-leishmanial Drugs’. DNDi also shared a booth with partners, Médecins Sans Frontières (MSF) and the Leishmaniasis East Africa Platform (LEAP). More than 700 attendees from around the world gathered at this event. The presence of DNDi and partners definitely added an extra dimension to the meeting. DNDi was a proud sponsor of the meeting, sharing details about its activities through face-toface meetings with participants, and virtual networking with different partners. DNDi also thanks the organisers; especially Dr C.M. Gupta, from the Central Drug Research Institute, Lucknow (CDRI), India, current partners, and other sponsors who helped make WorldLeish 4 a success! To learn more about the event, visit www.worldleish4.org or www.dndi.org.

Prof Nirmal K. Ganguly, Distinguished Biotechnology Fellow and Advisor, Translational Health Science and Technology Institute, India, gave his thoughts on the event: “It was exciting to be able to see the results budding from DNDi’s research partnerships in action. As a founding partner of DNDi, it is gratifying to see its unique model delivering strong research collaborations which are tying together best science in the laboratory with the realities of treating patients in remote areas. The diverse set of partners here and their unique and esteemed contributions represent the value that PDPs contribute to the building of long-lasting solutions for the most neglected.”